Home > Insider Trading > Filing (0001209191-18-060311)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1604464	Atara Biotherapeutics Inc.	ATRA	Biological Products, (No Disgnostic Substances) (2836)	460920988

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1612096	E. Isaac Ciechanover	611 Gateway Boulevard Suite 900 South San Francisco CA 94080	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-11-28	2,700	$38.65	32,578	No	4	S	Indirect	See footnote
Common Stock	Disposition	2018-11-28	1,200	$39.54	31,378	No	4	S	Indirect	See footnote
Common Stock	Disposition	2018-11-29	1,400	$41.13	29,978	No	4	S	Indirect	See footnote
Common Stock	Disposition	2018-11-29	2,500	$42.26	27,478	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	733,285	Direct

Footnotes

Transaction pursuant to Rule 10b5-1 Plan adopted January 23, 2018.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.14 to $39.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $39.705. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.65 to $41.63. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.68 to $42.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.